control mechanism specific for eosinophil proliferation and independent of other haemo-A paradigm shift, championed largely by cellular immunologists, has redefined poietic cell lineages; (2) eosinophilia is a characteristic feature of the pulmonary late asthma as an immune mediated phenomenon characterised by an interleukin 5 phase reaction and the extent of this reaction correlates strongly with various indices of clin-(IL-5) driven eosinophilic bronchitis. This change in emphasis has provoked intense ical severity in asthma; 2 and (3) eosinophil derived granule proteins are responsible for interest in the possibility that inhibitors of IL-5 production, or antagonists of its the destruction of the respiratory epithelium, mucosal oedema, bronchial hyperreactivity, activity, will provide a new generation of anti-asthma drugs.
IL-5, can stimulate eosinophil production in vitro, experiments with IL-5 transgenic and IL-5 deficient mice have shown that the expression Resistance to helminthic infections has prob-of IL-5 by T lymphocytes is both a necessary ably provided the selective pressure for the and sufficient condition for the proliferation of evolution of eosinophils although, para-eosinophils. 4 5 Furthermore, the lungs of allerdoxically, perhaps the commonest clinical gen sensitised mice deficient in IL-5 do not manifestation of tissue specific eosinophilia in develop the typical histological and functional modern western society is allergic disease. Until changes of asthma (including reactive eosthe last decade asthma was thought of in terms inophilia) when challenged, despite a proof bronchial hyperreactivity or mast cell in-gressive rise in allergen specific IgE. However, stability. Pulmonary eosinophilia was either pulmonary eosinophilia, tissue destruction, and ignored or interpreted as a mechanism for con-air flow limitation follow allergen challenge taining the pro-inflammatory effects of mast when IL-5 expression is reconstituted in these cell degranulation. Drug therapy based on these IL-5 deficient mice. 5 ideas has proved to be either ineffective, as with the so called "mast cell stabilisers", or has lacked specificity, as with the 2 adrenergic  -5    agonists and glucocorticosteroids. In fact, the Given these findings, a simple model of asthma narrow toxic to therapeutic ratio allowed by is proposed. Activation of the cellular immune most of the conventional anti-asthma agents system results in the production of IL-5 which, may have contributed in part to the alarming in turn, locates to the bone marrow via the increase in asthma related morbidity and morblood to stimulate the production of eostality. One possible strategy in the search for less toxic  The expression of most cytokine genes is suggesting that small molecules may be capable of blocking the interaction. Too little is known of the interaction with the chain or the signalling mechanisms to predict whether these might also be drug targets. Despite the lack of small molecules or basic information which might allow the rational design of antagonists, studies with antibodies suggest that antagonists will be clinically efficacious. Competitive blockade of IL-5 with anti-IL-5 antibody has been demonstrated in vivo. In these experiments, parasite or allergen induced eosinophilia was completely abrogated when animals were pretreated or treated after infestation with an anti-IL-5 antibody. This antibody did not block the effect of IL-3 or GM-CSF on other granulocytes. 7 Sch 55700 is a humanised variant of a rat monoclonal antibody against human IL-5. When given one hour before challenge to Ascaris responsive body has been shown to reduce the peripheral blood eosinophil count in IL-5 transgenic mice to control levels for several weeks. 9 Whether sporin A function as inhibitors of transcription of a number of genes, including IL-5. the antibody acts by blocking the binding of IL-5 to its receptor or whether cells expressing Given the biological evidence that the expression of IL-5 is independently regulated, it is the receptor are eliminated by an immune mechanism is a matter of debate. Nevertheless, reasonable to propose that, within the complex machinery controlling transcription, there must these experiments indicate that the IL-5 receptor is also a potential drug target. occur IL-5 specific events. IL-5 is an inducible gene which responds to activation of the T Although anti-IL-5 antibody therapy shows great promise, the fact is that most asthmatic cell receptor. 6 There appears to be a complex machinery in the 5′ or promoter region of the patients are well controlled on low to moderate dosages of inhaled glucocorticosteroid. If clingene which is based on the conserved lymphoid element (CLEO). This element seems to me-ical trials prove humanised anti-IL-5 antibody to be efficacious, then the problems of cost, diate transcription as well as integrating the action of the multiple DNA elements involved availability and administration will probably limit the use of IL-5 to the treatment of chronic in either activating or repressing transcription and possibly even translation. The final effect severe asthma or asthma that is refractory to conventional therapy. For those patients of this process is manifest as changes in the rate of initiation of IL-5 gene transcription. already well controlled on inhaled glucocorticosteroids, however, the reasons for inWhile the IL-5 gene promoter contains many sequence motifs common to other genes, our stituting anti-IL-5 therapy would probably reduce to issues of patient compliance, acstudies have identified control regions in the 5′ region of the IL-5 gene which appear to be ceptability and, possibly, cost.
Undoubtedly the effectiveness of an antibody gene restricted.
If new drugs can be found which target these in the clinic will strengthen the argument for investment in the search for small molecule gene specific regions in the IL-5 promoter, they may provide the therapeutic specificity which antagonists since modern techniques for producing biologically active antibody fragments steroids and cyclosporin A lack. make this a distinct possibility.
 IL-5 interacts with a receptor heterodimer consisting of a cytokine specific chain and a   Although anti-IL-5 blockade promises target signal transducing chain which is common to the receptors for GM-CSF and IL-3. No specificity, it might also compromise immunity to parasites and exacerbate a small proportion small molecule antagonists of any cytokine have yet been described. Pessimists would say that of cancers. 10 For example, parasite infestation may define a subgroup of patients in whom such multipoint interactions will be impossible to block with a small molecule. On the other anti-IL-5 treatment is a contraindication. So little is known about the role of reactive eoshand, mutation of a single amino acid in IL-5 can result in a 100 fold decrease in activity, inophilia in mucosal immunity and parasite group.bmj.com on July 6, 2017 -Published by http://thorax.bmj.com/ Downloaded from treatment for asthma. 
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